Which big pharma firms are best at digital?New research by The Worldcom Public Relations Group has ranked pharmaceutical companies according to their usage of digital Share XWhich big pharma firms are best at digital?https://pharmaphorum.com/views-analysis-digital/which-big-pharma-firms-are-best-at-digital/
FDA approves Bayer/Janssen’s Xarelto in new blood clot prevention useBayer and Janssen’s novel oral anticoagulant (NOAC) Xarelto has a new string to its bow after the FDA Share XFDA approves Bayer/Janssen’s Xarelto in new blood clot prevention usehttps://pharmaphorum.com/news/fda-approves-bayer-janssens-xarelto-in-new-blood-clot-prevention-use/
BI signs KRAS deal with India’s Lupin, as pharma awaits key Amgen dataBoehringer Ingelheim has signed a deal with India’s Lupin to develop and market a potential cancer drug targeting Share XBI signs KRAS deal with India’s Lupin, as pharma awaits key Amgen datahttps://pharmaphorum.com/news/bi-signs-kras-deal-with-indias-lupin-as-pharma-awaits-key-amgen-data/
Boehringer jumps on KRAS cancer drug bandwagon with MD AndersonBoehringer Ingelheim has become the latest pharma company to investigate KRAS as a potential target for cancer drugs, Share XBoehringer jumps on KRAS cancer drug bandwagon with MD Andersonhttps://pharmaphorum.com/news/boehringer-jumps-on-kras-cancer-drug-bandwagon-with-md-anderson/
Boehringer announces IPF deal with Korea’s Bridge TherapeuticsBoehringer Ingelheim and South Korean biotech Bridge Biotherapeutics have announced a deal to develop the latter’s drug for Share XBoehringer announces IPF deal with Korea’s Bridge Therapeuticshttps://pharmaphorum.com/news/boehringer-announces-ipf-deal-with-koreas-bridge-therapeutics/
FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failureEli Lilly and Boehringer Ingelheim’s Jardiance was the first diabetes drug to lower the risk of cardiovascular disease Share XFDA fast-tracks Lilly/Boehringer’s Jardiance for heart failurehttps://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-for-heart-failure/
Boehringer adds to obesity alliance with Denmark’s GubraTwo years after they started working together, Boehringer Ingelheim and Gubra have taken their obesity collaboration to a Share XBoehringer adds to obesity alliance with Denmark’s Gubrahttps://pharmaphorum.com/news/boehringer-obesity-denmarks-gubra/
Boehringer looks to enhance COPD care with new registryBoehringer Ingelheim and Optimum Patient Care are launching a new patient registry, APEX COPD (Advancing the Patient Experience Share XBoehringer looks to enhance COPD care with new registryhttps://pharmaphorum.com/news/boehringer-enhance-copd-care-new-registry/
AbbVie gets crucial US approval for psoriasis drug SkyriziWith one eye on life without its ageing $20 billion-a-year blockbuster Humira, AbbVie has got its psoriasis drug Share XAbbVie gets crucial US approval for psoriasis drug Skyrizihttps://pharmaphorum.com/news/abbvie-gets-crucial-us-approval-for-psoriasis-drug-skyrizi/
